Moderna Inc.: These Are The 4 Biggest Challenges That Bears Are Counting On! 

Moderna reported its Quarterly Earnings recently and managed a decent performance. Positives from the quarter included advancements in Moderna’s respiratory vaccine portfolio, particularly with mRNA-1273, its COVID-19 vaccine, and new RSV vaccine, mRESVIA. Notably, mRNA-1273 continues to be a significant product in combating COVID-19 with substantial hospitalization rates reported from the CDC for the ’23/’24 season. The recent launch of mRESVIA in the U.S. and approval in Europe has been a crucial development, potentially broadening Moderna’s market reach and impact on global health.